Skip to main content

Table 2 Basic characteristics for patients with different FIB levels

From: Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study

 

Fibrinogen, mg/dL

P value

FIB-L (1.76–2.91)

N = 137

FIB-M (2.93–3.62)

N = 137

FIB-H (3.63–8.14)

N = 137

FIB, mg/dL

2.53 ± 0.27

3.28 ± 0.20

4.21 ± 0.55

< 0.001

Age, year

60.0 ± 10.0

60.2 ± 10.0

61.7 ± 11.2

0.348

Male sex, %

75.2

81.0

75.2

0.414

BMI, kg/m2

24.83 ± 3.17

25.02 ± 3.17

24.4 ± 3.45

0.446

Past PCI or CABG, %

16.8

17.5

23.4

0.319

Past MI, %

13.9

14.6

19.0

0.456

Smoking, %

54.7

58.4

56.9

0.828

Diabetes, %

16.1

27.7

31.4

0.009

Hypertension, %

59.9

49.6

49.6

0.147

Family history, %

45.3

46.7

28.5

0.003

Ejection fraction, %

59.6 ± 11.3

57.1 ± 13.7

58.6 ± 11.7

0.247

HGB, g/L

139.6 ± 17.2

139.7 ± 17.6

138.5 ± 16.3

0.828

Platelet, 103 cells/dL

181.92 ± 71.51

182.89 ± 51.07

210.04 ± 71.01

< 0.001

Creatinine, mg/dL

69.89 ± 24.97

68.74 ± 18.56

75.07 ± 50.39

0.271

HbA1c, %

6.08 ± 1.06

6.51 ± 1.50

6.72 ± 1.55

0.001

FBG, mmol/L

6.02 ± 2.28

6.36 ± 2.16

6.77 ± 2.80

0.043

LDL-C, mg/dL

2.27 ± 0.79

2.26 ± 0.78

2.14 ± 0.89

0.376

hsCRP, mg/dL

1.48 ± 1.78

2.19 ± 2.18

3.50 ± 2.51

< 0.001

CKMB, U/L

33.06 ± 48.26

38.48 ± 54.07

42.35 ± 64.79

0.809

Pro-BNP, pg/mL

473.09 ± 967.43

724.36 ± 1221.05

1343.61 ± 3244.03

< 0.001

Medication at discharge

 Aspirin, %

100

100

100

a

 Clopidogrel, %

100

100

100

a

 Statin, %

96.4

98.5

98.5

0.360

 ACEI/ARB, %

94.9

94.2

88.3

0.078

 CCB, %

26.3

19.0

27.7

0.278

 ACS type

0.045

 UA

58.4

56.9

52.3

 

 STEMI

21.9

29.9

37.2

 

 NonSTEMI

19.7

13.1

10.9

 

 MACE, %

31.4

44.5

41.6

0.019

 All-cause death, %

2.92

4.38

9.49

0.032

  1. Data are presented as mean ± SD or number (%)
  2. FIB fibrinogen, BMI body mass index, Past PCI or CABG past percutaneous coronary intervention or coronary artery bypass grafting, Past MI past myocardial infarction, HGB hemoglobin, HbA1c hemoglobin A1c, FBG fasting blood glucose, hsCRP hypersensitive C-reactive protein, CKMB creatine kinase isoenzymes MB, Pro-BNP pro-B-type natriuretic peptide, LDL-C low-density lipoprotein cholesterol, PLT platelets, ACEI angiotensin-converting enzyme inhibition, ARB angiotensin receptor blocker, CCB calcium channel blocker, ACS acute coronary syndromes, UA unstable angina, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, MACE major adverse cardiovascular events
  3. “a” represents P value = 1
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840